Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:REGN) in comparison to its major competitors within the Biotechnology industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Regeneron Pharmaceuticals Background
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals Inc | 28.58 | 3.95 | 8.42 | 2.73% | $0.83 | $2.71 | -0.54% |
AbbVie Inc | 48.91 | 36.25 | 5.35 | 14.8% | $4.49 | $8.22 | 0.7% |
Amgen Inc | 44.96 | 33.62 | 5.73 | -2.01% | $2.15 | $4.25 | 21.98% |
Vertex Pharmaceuticals Inc | 28.59 | 6.13 | 11.28 | 6.09% | $1.34 | $2.35 | 13.3% |
Gilead Sciences Inc | 188.50 | 4.82 | 3.10 | -20.66% | $-3.54 | $5.13 | 5.26% |
Biogen Inc | 28.75 | 2.20 | 3.47 | 2.62% | $0.68 | $1.75 | -7.0% |
BioNTech SE | 182.94 | 1.04 | 7.61 | -1.57% | $-0.29 | $0.13 | -85.31% |
Genmab A/S | 24.64 | 4.07 | 7.58 | 4.13% | $1.72 | $3.96 | 46.19% |
Biomarin Pharmaceutical Inc | 72.61 | 2.88 | 6 | 1.77% | $0.14 | $0.52 | 8.79% |
Neurocrine Biosciences Inc | 38.56 | 5.99 | 7.35 | 6.98% | $0.04 | $0.51 | 25.05% |
Incyte Corp | 17.23 | 2.37 | 3.42 | 3.2% | $0.26 | $0.82 | 8.93% |
Sarepta Therapeutics Inc | 308.70 | 13.05 | 9 | 3.97% | $0.05 | $0.36 | 63.1% |
United Therapeutics Corp | 12.89 | 2.26 | 5.42 | 5.42% | $0.43 | $0.6 | 33.7% |
Roivant Sciences Ltd | 2.17 | 1.51 | 74.41 | 144.81% | $5.11 | $0.03 | 117.8% |
Average | 76.88 | 8.94 | 11.52 | 13.04% | $0.97 | $2.2 | 19.42% |